119 related articles for article (PubMed ID: 12941334)
1. Bone-targeted Src kinase inhibitors: novel pyrrolo- and pyrazolopyrimidine analogues.
Sundaramoorthi R; Shakespeare WC; Keenan TP; Metcalf CA; Wang Y; Mani U; Taylor M; Liu S; Bohacek RS; Narula SS; Dalgarno DC; van Schravandijk MR; Violette SM; Liou S; Adams S; Ram MK; Keats JA; Weigle M; Sawyer TK; Weigele M
Bioorg Med Chem Lett; 2003 Sep; 13(18):3063-6. PubMed ID: 12941334
[TBL] [Abstract][Full Text] [Related]
2. Bone-targeted 2,6,9-trisubstituted purines: novel inhibitors of Src tyrosine kinase for the treatment of bone diseases.
Wang Y; Metcalf CA; Shakespeare WC; Sundaramoorthi R; Keenan TP; Bohacek RS; van Schravendijk MR; Violette SM; Narula SS; Dalgarno DC; Haraldson C; Keats J; Liou S; Mani U; Pradeepan S; Ram M; Adams S; Weigele M; Sawyer TK
Bioorg Med Chem Lett; 2003 Sep; 13(18):3067-70. PubMed ID: 12941335
[TBL] [Abstract][Full Text] [Related]
3. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
[TBL] [Abstract][Full Text] [Related]
4. Novel bone-targeted Src tyrosine kinase inhibitor drug discovery.
Shakespeare WC; Metcalf CA; Wang Y; Sundaramoorthi R; Keenan T; Weigele M; Bohacek RS; Dalgarno DC; Sawyer TK
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):729-41. PubMed ID: 14579523
[TBL] [Abstract][Full Text] [Related]
5. Targeting protein kinases for bone disease: discovery and development of Src inhibitors.
Metcalf CA; van Schravendijk MR; Dalgarno DC; Sawyer TK
Curr Pharm Des; 2002; 8(23):2049-75. PubMed ID: 12171518
[TBL] [Abstract][Full Text] [Related]
6. SAR of carbon-linked, 2-substituted purines: synthesis and characterization of AP23451 as a novel bone-targeted inhibitor of Src tyrosine kinase with in vivo anti-resorptive activity.
Shakespeare WC; Wang Y; Bohacek R; Keenan T; Sundaramoorthi R; Metcalf C; Dilauro A; Roeloffzen S; Liu S; Saltmarsh J; Paramanathan G; Dalgarno D; Narula S; Pradeepan S; van Schravendijk MR; Keats J; Ram M; Liou S; Adams S; Wardwell S; Bogus J; Iuliucci J; Weigele M; Xing L; Boyce B; Sawyer TK
Chem Biol Drug Des; 2008 Feb; 71(2):97-105. PubMed ID: 18179464
[TBL] [Abstract][Full Text] [Related]
7. Bone-targeted pyrido[2,3-d]pyrimidin-7-ones: potent inhibitors of Src tyrosine kinase as novel antiresorptive agents.
Vu CB; Luke GP; Kawahata N; Shakespeare WC; Wang Y; Sundaramoorthi R; Metcalf CA; Keenan TP; Pradeepan S; Corpuz E; Merry T; Bohacek RS; Dalgarno DC; Narula SS; van Schravendijk MR; Ram MK; Adams S; Liou S; Keats JA; Violette SM; Guan W; Weigele M; Sawyer TK
Bioorg Med Chem Lett; 2003 Sep; 13(18):3071-4. PubMed ID: 12941336
[TBL] [Abstract][Full Text] [Related]
8. 7-Pyrrolidinyl- and 7-piperidinyl-5-aryl-pyrrolo[2,3-d]pyrimidines--potent inhibitors of the tyrosine kinase c-Src.
Altmann E; Missbach M; Green J; Susa M; Wagenknecht HA; Widler L
Bioorg Med Chem Lett; 2001 Mar; 11(6):853-6. PubMed ID: 11277536
[TBL] [Abstract][Full Text] [Related]
9. 7-Alkyl- and 7-cycloalkyl-5-aryl-pyrrolo[2,3-d]pyrimidines--potent inhibitors of the tyrosine kinase c-Src.
Widler L; Green J; Missbach M; Susa M; Altmann E
Bioorg Med Chem Lett; 2001 Mar; 11(6):849-52. PubMed ID: 11277535
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity.
Shakespeare W; Yang M; Bohacek R; Cerasoli F; Stebbins K; Sundaramoorthi R; Azimioara M; Vu C; Pradeepan S; Metcalf C; Haraldson C; Merry T; Dalgarno D; Narula S; Hatada M; Lu X; van Schravendijk MR; Adams S; Violette S; Smith J; Guan W; Bartlett C; Herson J; Iuliucci J; Weigele M; Sawyer T
Proc Natl Acad Sci U S A; 2000 Aug; 97(17):9373-8. PubMed ID: 10944210
[TBL] [Abstract][Full Text] [Related]
11. Identification of new pyrrolo[2,3-d]pyrimidines as Src tyrosine kinase inhibitors in vitro active against Glioblastoma.
Musumeci F; Fallacara AL; Brullo C; Grossi G; Botta L; Calandro P; Chiariello M; Kissova M; Crespan E; Maga G; Schenone S
Eur J Med Chem; 2017 Feb; 127():369-378. PubMed ID: 28076826
[TBL] [Abstract][Full Text] [Related]
12. Inhibitor scaffolds as new allele specific kinase substrates.
Kraybill BC; Elkin LL; Blethrow JD; Morgan DO; Shokat KM
J Am Chem Soc; 2002 Oct; 124(41):12118-28. PubMed ID: 12371851
[TBL] [Abstract][Full Text] [Related]
13. Substituted 5,7-diphenyl-pyrrolo[2,3d]pyrimidines: potent inhibitors of the tyrosine kinase c-Src.
Missbach M; Altmann E; Widler L; Susa M; Buchdunger E; Mett H; Meyer T; Green J
Bioorg Med Chem Lett; 2000 May; 10(9):945-9. PubMed ID: 10853665
[TBL] [Abstract][Full Text] [Related]
14. The design, synthesis and activity of non-ATP competitive inhibitors of pp60(c-src) tyrosine kinase. Part 1: hydroxynaphthalene derivatives.
Marsilje TH; Milkiewicz KL; Hangauer DG
Bioorg Med Chem Lett; 2000 Mar; 10(5):477-81. PubMed ID: 10743952
[TBL] [Abstract][Full Text] [Related]
15. N(7)-substituted-5-aryl-pyrrolo[2,3-d]pyrimidines represent a versatile class of potent inhibitors of the tyrosine kinase c-Src.
Altmann E; Widler L; Missbach M
Mini Rev Med Chem; 2002 Jun; 2(3):201-8. PubMed ID: 12370062
[TBL] [Abstract][Full Text] [Related]
16. The design, synthesis and activity of non-ATP competitive inhibitors of pp60(c-src) tyrosine kinase. Part 2: hydroxyindole derivatives.
Milkiewicz KL; Marsilje TH; Woodworth RP; Bifulco N; Hangauer MJ; Hangauer DG
Bioorg Med Chem Lett; 2000 Mar; 10(5):483-6. PubMed ID: 10743953
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases.
Rucci N; Susa M; Teti A
Anticancer Agents Med Chem; 2008 Apr; 8(3):342-9. PubMed ID: 18393792
[TBL] [Abstract][Full Text] [Related]
19. Novel heterocyclic-fused pyrimidine derivatives: synthesis, molecular modeling and pharmacological screening.
Arafa RK; Nour MS; El-Sayed NA
Eur J Med Chem; 2013 Nov; 69():498-507. PubMed ID: 24090920
[TBL] [Abstract][Full Text] [Related]
20. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.
Traxler PM; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Med Chem; 1996 Jun; 39(12):2285-92. PubMed ID: 8691423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
